<DOC>
	<DOCNO>NCT01409031</DOCNO>
	<brief_summary>The purpose study determine whether intravenous sildenafil reduces pulmonary artery pressure improve oxygenation near-term term infant persistent pulmonary hypertension .</brief_summary>
	<brief_title>Study Sildenafil Treat Newborns With Persistent Pulmonary Hypertension</brief_title>
	<detailed_description>Term infant respiratory failure persistent pulmonary hypertension ( PPHN ) among critically ill infant NICU , significant mortality morbidity report even infant moderate disease . Currently , management largely supportive , include oxygen , mechanical ventilation ( conventional high frequency ventilation ) , exogenous surfactant therapy . Inhaled nitric oxide ( iNO ) pulmonary vasodilator approve treatment hypoxic respiratory failure ( HRF ) PPHN newborn 1999 base clinical trial show reduction need rescue treatment extracorporeal membrane oxygenation ( ECMO ) . One promising therapy decrease pulmonary arterial pressure improve oxygenation sildenafil . Sildenafil cGMP-specific phosphodiesterase inhibitor cause relatively selective pulmonary vasodilation . The use intravenous ( IV ) sildenafil recently FDA approve use adult PPHN . A pilot trial study dose response pharmacokinetics 36 term newborn PPHN find IV sildenafil well tolerate potential induce mark improvement oxygenation . The data pilot trial provide background support dose regimen Phase II trial . We hypothesize IV sildenafil acutely reduce pulmonary artery pressure improve oxygenation near-term term infant PPHN , thus reduce need rescue therapy iNO and/or ECMO .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Sildenafil Citrate</mesh_term>
	<criteria>Signed informed consent legally acceptable guardian PPHN hypoxemic respiratory failure associate : Idiopathic PPHN Meconium aspiration syndrome Respiratory distress syndrome Sepsis Pneumonia Greater equal 35 week gestation Age enrollment le 72 hour Moderate hypoxemic respiratory failure , 12 &lt; OI &lt; 35 ( oxygenation index , calculate FiO2 * mean airway pressure * 100 / postductal PaO2 ) Absence structural heart disease ( except patent ductus arteriosus , atrial septal defect &lt; 1cm , muscular ventricular septal defect &lt; 2mm ) Absence lethal congenital anomaly Not participate another concurrent experimental study Prior immediate need iNO ECMO Profound hypoxemia : qualifying PaO2 &lt; 30 mmHg , blood gas drawn within 30 minute start study drug infusion . Hypotension : Mean arterial pressure &lt; 35 mmHg Congenital heart disease , except patent ductus arteriosus , atrial septal defect &lt; 1cm , muscular ventricular septal defect &lt; 2mm Congenital diaphragmatic hernia lung hypoplasia syndrome , diagnose basis prolong oligohydramnios Active seizure Apgar score &lt; 3 5 minute Bleeding diathesis Receipt experimental drug device Receipt prohibit concurrent medication : Potent cytochrome P450 3A4 inhibitor ( e.g. , erythromycin , ketoconazole , itraconazole protease inhibitor ) Endothelin antagonist ( e.g . Tracleer/bosentan ) Intravenous nitrate nitric oxide donor Known hereditary degenerative retinal disorder retinitis pigmentosa . In opinion investigator , subject likely complete study would consider inappropriate study , reason .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>72 Hours</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>newborn</keyword>
	<keyword>respiratory failure</keyword>
	<keyword>pulmonary hypertension</keyword>
	<keyword>treatment</keyword>
</DOC>